股本结构
单位：万股
| 公告日期 | 2025-10-14 | 2025-11-07 | 2025-05-13 | 2025-04-29 | 2025-04-09 | 2025-03-31 |
|---|---|---|---|---|---|---|
| 证券总股本 | 181.41 | 163.91 | 149.42 | 149.42 | 123.62 | 55.40 |
| 普通股本 | 181.41 | 163.91 | 149.42 | 149.42 | 123.62 | 55.40 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-10-10 | 2025-09-30 | 2025-05-12 | 2025-04-28 | 2025-04-08 | 2024-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-10-14 | 181.41 | 未披露 |
更多>>
Common stock offered 175,000 shares by the company
|
2025-10-10 |
| 2025-11-07 | 163.91 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Exercise of April 2025 Prefunded Warrants
|
2025-09-30 |
| 2025-05-13 | 149.42 | 未披露 | 定期报告 | 2025-05-12 |
| 2025-04-29 | 149.42 | 未披露 | 定期报告 | 2025-04-28 |
| 2025-04-09 | 123.62 | 未披露 |
更多>>
The exercise of the Existing Warrants resulted in the Company issuing 682,203 shares of Common Stock.
|
2025-04-08 |
| 2025-03-31 | 55.40 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock in connection with January 2024 Offering, net of issuance costs of $711,031
Issuance of common stock in connection with Bridge Note Financing
Issuance of common stock in connection with June 2024 Offering, net of issuance costs of $1,133,419
Exercise of Series D Warrants
|
2024-12-31 |
| 2024-11-13 | 55.29 | 未披露 |
更多>>
a reverse stock split of its shares of common stock at a ratio of 1-for-50
|
2024-11-18 |
| 2024-11-13 | 2762.47 | 未披露 | 定期报告 | 2024-11-13 |
| 2024-11-07 | 2688.40 | 未披露 | 定期报告 | 2024-11-04 |
| 2024-11-07 | 1782.73 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Exercise of June 2024 Prefunded Warrants
Exercise of Series D Warrants
|
2024-09-30 |
| 2024-09-10 | 1654.81 | 未披露 | 定期报告 | 2024-09-09 |
| 2024-08-28 | 1285.38 | 未披露 | 定期报告 | 2024-08-27 |
| 2024-08-14 | 625.22 | 未披露 | 定期报告 | 2024-08-06 |
| 2024-07-16 | 352.99 | 未披露 | 定期报告 | 2024-07-03 |
| 2024-08-14 | 258.41 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Exercise of January 2024 Prefunded Warrants
Issuance of Common Stock in connection with Bridge Note Financing
Issuance of Common Stock in connection with June 2024 Offering, net of issuance costs of $
|
2024-06-30 |
| 2024-06-28 | 593.21 | 未披露 |
更多>>
Units offered 5,368,098 Units by the company
|
2024-06-28 |
| 2024-06-24 | 56.40 | 未披露 | 定期报告 | 2024-06-21 |
| 2024-06-17 | 56.40 | 未披露 |
更多>>
1-for-8 the Reverse Stock Split
|
2024-06-20 |
| 2024-06-17 | 451.18 | 未披露 | 定期报告 | 2024-06-14 |
| 2024-05-15 | 290.44 | 未披露 | 定期报告 | 2024-05-01 |
| 2024-03-28 | 268.84 | 未披露 | 定期报告 | 2024-03-28 |
| 2023-12-29 | 177.69 | 未披露 |
更多>>
Common stock offered 537,768 shares by the company
|
2024-01-02 |
| 2023-11-09 | 123.91 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock, net of issuance costs of $413,544
|
2023-09-30 |
| 2023-08-28 | 123.93 | 未披露 |
更多>>
Common stock offered 216,000 shares by the company
|
2023-08-28 |
| 2023-08-14 | 102.33 | 未披露 | 定期报告 | 2023-08-04 |
| 2023-07-21 | 102.33 | 未披露 |
更多>>
Bluejay Diagnostics, Inc. announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-20.
|
2023-07-24 |
| 2023-07-21 | 2046.69 | 未披露 | 定期报告 | 2023-07-21 |
| 2023-03-20 | 2045.91 | 未披露 | 定期报告 | 2023-02-28 |
| 2023-03-20 | 2021.53 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Exercise of common stock Series B Warrants
Exercise of stock options
|
2022-12-31 |
| 2022-08-10 | 2015.23 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Exercise of common stock Series B Warrants
|
2022-06-30 |
| 2022-03-10 | 2015.12 | 未披露 | 定期报告 | 2022-02-28 |
| 2022-03-10 | 2011.22 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of common stock warrants
Accretion of redeemable, convertible preferred stock to redemption value
Conversion of convertible debentures into Series D preferred stock
Conversion of redeemable, convertible preferred stock into common stock
Conversion of Amended 2017 Convertible Notes into common stock
Issuance of common stock from exercise of stock options
Issuance of common stock in initial public offering, net of offering costs of $2,750,601
Issuance of common stock from exercise of warrants
|
2021-12-31 |
| 2021-12-16 | 1950.17 | 未披露 | 定期报告 | 2021-12-06 |
| 2021-11-12 | 1269.43 | 未披露 |
更多>>
1.The number of shares of common stock outstanding is based on 10,534,265 shares of common stock issued and outstanding as of October 20, 2021.
|
2021-11-10 |
Common stock offered 175,000 shares by the company
From June 30, 2025 to September 30, 2025
Exercise of April 2025 Prefunded Warrants
The exercise of the Existing Warrants resulted in the Company issuing 682,203 shares of Common Stock.
From December 31, 2023 to December 31, 2024
Issuance of common stock in connection with January 2024 Offering, net of issuance costs of $711,031
Issuance of common stock in connection with Bridge Note Financing
Issuance of common stock in connection with June 2024 Offering, net of issuance costs of $1,133,419
Exercise of Series D Warrants
a reverse stock split of its shares of common stock at a ratio of 1-for-50
From June 30, 2024 to September 30, 2024
Exercise of June 2024 Prefunded Warrants
Exercise of Series D Warrants
From March 31, 2024 to June 30, 2024
Exercise of January 2024 Prefunded Warrants
Issuance of Common Stock in connection with Bridge Note Financing
Issuance of Common Stock in connection with June 2024 Offering, net of issuance costs of $
Units offered 5,368,098 Units by the company
1-for-8 the Reverse Stock Split
Common stock offered 537,768 shares by the company
From June 30, 2023 to September 30, 2023
Issuance of common stock, net of issuance costs of $413,544
Common stock offered 216,000 shares by the company
Bluejay Diagnostics, Inc. announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-20.
From December 31, 2021 to December 31, 2022
Exercise of common stock Series B Warrants
Exercise of stock options
From March 31, 2022 to June 30, 2022
Exercise of common stock Series B Warrants
From December 31, 2020 to December 31, 2021
Exercise of common stock warrants
Accretion of redeemable, convertible preferred stock to redemption value
Conversion of convertible debentures into Series D preferred stock
Conversion of redeemable, convertible preferred stock into common stock
Conversion of Amended 2017 Convertible Notes into common stock
Issuance of common stock from exercise of stock options
Issuance of common stock in initial public offering, net of offering costs of $2,750,601
Issuance of common stock from exercise of warrants
1.The number of shares of common stock outstanding is based on 10,534,265 shares of common stock issued and outstanding as of October 20, 2021.